Boston Scientific Corporation BSX today announced it has received approval from the U.S. Food and
Drug Administration (FDA) to market its 2.25 mm PROMUS ^® Everolimus-Eluting Coronary Stent System for use in vessels as small as 2.25 mm in diameter. The Company plans to immediately launch the product in the U.S.
The PROMUS Stent features a thin-strut, open-cell design to allow for excellent flexibility and conformability in the vessel. The low-profile stent and catheter tip help enhance deliverability, especially in small vessels.
The PROMUS Stent is supported by the SPIRIT clinical trial program, which demonstrates that the controlled release of everolimus results in low levels of late loss and a strong safety profile. The addition of this stent expands
the available size matrix of Boston Scientific's PROMUS Stent portfolio to include diameters from 2.25 to 4.0 mm and lengths from 8 mm to 28 mm.
"The PROMUS Stent has demonstrated outstanding deliverability, low late loss and excellent safety in numerous clinical trials and extensive real-world practice," said Dean J. Kereiakes, M.D., FACC, Medical Director, The Christ
Hospital Heart and Vascular Center and The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital, and Professor of Clinical Medicine, Ohio State University. "These benefits make the PROMUS 2.25 mm
Stent an attractive option for U.S. physicians treating patients with small vessels."
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in